Neumirna Therapeutics:
Neumirna Therapeutics is a biotechnology company developing RNA‑based therapies for neurological disorders dedicated to transforming patients’ lives.
Founded in 2020 in Copenhagen, Denmark by Dr. Henrik Klitgaard and Prof. Sakari Kauppinen, the company is advancing therapies for neurological diseases through the modulation of microRNAs.
Neumirna’s portfolio includes a clinical candidate, NMT.001, for drug‑resistant epilepsy, and a preclinical program in Parkinson’s disease. The company completed its Series A financing in January 2025 and is supported by Invivo Partners, Angelini Ventures and Innovestor, with the founders remaining actively involved.
For more information, please contact:
Phone +45 2422 1969